These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 19849959)

  • 21. Treatment of advanced HIV disease in antiretroviral-naïve HIV-1-infected patients receiving once-daily atazanavir/ritonavir or twice-daily lopinavir/ritonavir, each in combination with tenofovir disoproxil fumarate and emtricitabine.
    Uy J; Yang R; Wirtz V; Sheppard L; Farajallah A; McGrath D
    AIDS Care; 2011 Nov; 23(11):1500-4. PubMed ID: 21732894
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-term efficacy and safety of once-daily nevirapine in combination with tenofovir and emtricitabine in the treatment of HIV-infected patients: a 72-week prospective multicenter study (TENOR-trial).
    Weberschock T; Gholam P; Hueter E; Flux K; ; Hartmann M
    Eur J Med Res; 2009; 14(12):516-9. PubMed ID: 20149984
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A 48-week study of fat molecular alterations in HIV naive patients starting tenofovir/emtricitabine with lopinavir/ritonavir or efavirenz.
    Domingo P; Gutierrez Mdel M; Gallego-Escuredo JM; Torres F; Mateo MG; Villarroya J; Lamarca K; Domingo JC; Vidal F; Villarroya F; Giralt M
    J Acquir Immune Defic Syndr; 2014 Aug; 66(5):457-65. PubMed ID: 24820106
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cobicistat versus ritonavir as a pharmacoenhancer of atazanavir plus emtricitabine/tenofovir disoproxil fumarate in treatment-naive HIV type 1-infected patients: week 48 results.
    Gallant JE; Koenig E; Andrade-Villanueva J; Chetchotisakd P; DeJesus E; Antunes F; Arastéh K; Moyle G; Rizzardini G; Fehr J; Liu Y; Zhong L; Callebaut C; Szwarcberg J; Rhee MS; Cheng AK
    J Infect Dis; 2013 Jul; 208(1):32-9. PubMed ID: 23532097
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial.
    DeJesus E; Rockstroh JK; Henry K; Molina JM; Gathe J; Ramanathan S; Wei X; Yale K; Szwarcberg J; White K; Cheng AK; Kearney BP;
    Lancet; 2012 Jun; 379(9835):2429-2438. PubMed ID: 22748590
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Increased antiretroviral potency by the addition of enfuvirtide to a four-drug regimen in antiretroviral-naive, HIV-infected patients.
    Moltó J; Ruiz L; Valle M; Martinez-Picado J; Bonjoch A; Bravo I; Negredo E; Heilek-Sneider GM; Clotet B
    Antivir Ther; 2006; 11(1):47-51. PubMed ID: 16518959
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Brief Report: Cobicistat Compared With Ritonavir as a Pharmacoenhancer for Atazanavir in Combination With Emtricitabine/Tenofovir Disoproxil Fumarate: Week 144 Results.
    Gallant JE; Koenig E; Andrade-Villanueva JF; Chetchotisakd P; DeJesus E; Antunes F; Arastéh K; Rizzardini G; Fehr J; Liu HC; Abram ME; Cao H; Szwarcberg J
    J Acquir Immune Defic Syndr; 2015 Jul; 69(3):338-40. PubMed ID: 26181707
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A simplification trial switching from nucleoside reverse transcriptase inhibitors to once-daily fixed-dose abacavir/lamivudine or tenofovir/emtricitabine in HIV-1-infected patients with virological suppression.
    Martínez E; Arranz JA; Podzamczer D; Loncá M; Sanz J; Barragán P; Ribera E; Knobel H; Roca V; Gutiérrez F; Blanco JL; Mallolas J; Llibre JM; Clotet B; Dalmau D; Segura F; Arribas JR; Cosín J; Barrufet P; Casas E; Ferrer E; Curran A; González A; Pich J; Cruceta A; Arnaiz JA; Miró JM; Gatell JM;
    J Acquir Immune Defic Syndr; 2009 Jul; 51(3):290-7. PubMed ID: 19398921
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Switching from twice-daily raltegravir plus tenofovir disoproxil fumarate/emtricitabine to once-daily elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate in virologically suppressed, HIV-1-infected subjects: 48 weeks data.
    Mills A; Crofoot G; Ortiz R; Rashbaum B; Towner W; Ward D; Brinson C; Kulkarni R; Garner W; Ebrahimi R; Cao H; Cheng A; Szwarcberg J
    HIV Clin Trials; 2014; 15(2):51-6. PubMed ID: 24710918
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Patient-reported outcomes in virologically suppressed, HIV-1-Infected subjects after switching to a simplified, single-tablet regimen of efavirenz, emtricitabine, and tenofovir DF.
    Hodder SL; Mounzer K; Dejesus E; Ebrahimi R; Grimm K; Esker S; Ecker J; Farajallah A; Flaherty JF;
    AIDS Patient Care STDS; 2010 Feb; 24(2):87-96. PubMed ID: 20156091
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacokinetics and inhibitory quotient of atazanavir/ritonavir versus lopinavir/ritonavir in HIV-infected, treatment-naive patients who participated in the CASTLE Study.
    Zhu L; Liao S; Child M; Zhang J; Persson A; Sevinsky H; Eley T; Xu X; Krystal M; Farajallah A; McGrath D; Molina JM; Bertz R
    J Antimicrob Chemother; 2012 Feb; 67(2):465-8. PubMed ID: 22121190
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antiretroviral drug exposure in the female genital tract: implications for oral pre- and post-exposure prophylaxis.
    Dumond JB; Yeh RF; Patterson KB; Corbett AH; Jung BH; Rezk NL; Bridges AS; Stewart PW; Cohen MS; Kashuba AD
    AIDS; 2007 Sep; 21(14):1899-907. PubMed ID: 17721097
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacokinetics of once-daily etravirine without and with once-daily darunavir/ritonavir in antiretroviral-naive HIV type-1-infected adults.
    DeJesus E; Lalezari JP; Osiyemi OO; Ruane PJ; Ryan R; Kakuda TN; Witek J
    Antivir Ther; 2010; 15(5):711-20. PubMed ID: 20710052
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Switch from a ZDV/3TC-based regimen to a completely once daily (QD) regimen of emtricitabine/tenofovir DF fixed dose combination plus a third QD agent (SONETT).
    Arasteh K; Weitner L; Fenske S; Kuhlmann B; Freiwald M; Ebrahimi R; Gallo L; Ranneberg R; Mertenskoetter T
    Eur J Med Res; 2009 May; 14(5):195-9. PubMed ID: 19541575
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tolerability of HIV postexposure prophylaxis with tenofovir/emtricitabine and lopinavir/ritonavir tablet formulation.
    Tosini W; Muller P; Prazuck T; Benabdelmoumen G; Peyrouse E; Christian B; Quertainmont Y; Bouvet E; Rabaud C
    AIDS; 2010 Sep; 24(15):2375-80. PubMed ID: 20729709
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Oral antiretroviral drugs as public health tools for HIV prevention: global implications for adherence, drug resistance, and the success of HIV treatment programs.
    Gupta RK; Wainberg MA; Brun-Vezinet F; Gatell JM; Albert J; Sönnerborg A; Nachega JB
    J Infect Dis; 2013 Jun; 207 Suppl 2(Suppl 2):S101-6. PubMed ID: 23687287
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment.
    Smith KY; Patel P; Fine D; Bellos N; Sloan L; Lackey P; Kumar PN; Sutherland-Phillips DH; Vavro C; Yau L; Wannamaker P; Shaefer MS;
    AIDS; 2009 Jul; 23(12):1547-56. PubMed ID: 19542866
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Suboptimal adherence to darunavir/ritonavir has minimal effect on efficacy compared with lopinavir/ritonavir in treatment-naive, HIV-infected patients: 96 week ARTEMIS data.
    Nelson M; Girard PM; Demasi R; Chen L; Smets E; Sekar V; Lavreys L
    J Antimicrob Chemother; 2010 Jul; 65(7):1505-9. PubMed ID: 20498120
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pilot pharmacokinetic study of human immunodeficiency virus-infected patients receiving tenofovir disoproxil fumarate (TDF): investigation of systemic and intracellular interactions between TDF and abacavir, lamivudine, or lopinavir-ritonavir.
    Pruvost A; Negredo E; Théodoro F; Puig J; Levi M; Ayen R; Grassi J; Clotet B
    Antimicrob Agents Chemother; 2009 May; 53(5):1937-43. PubMed ID: 19273671
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Steady-state amprenavir, tenofovir, and emtricitabine pharmacokinetics before and after reducing ritonavir boosting of a fosamprenavir/tenofovir/emtricitabine regimen from 200 mg to 100 mg once daily (TELEX II).
    Parks DA; Jennings HC; Taylor C; Pakes GE; Acosta EP
    HIV Clin Trials; 2009; 10(3):160-7. PubMed ID: 19632955
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.